Disease Landscape and Forecast Insights

The most common problems associated with treating dyslipidemia are identifying patients who need to be treated, determining how aggressively they should be treated, and then encouraging them to…

The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting…

Although agents available for controlling disease in mild ulcerative colitis (UC) are largely effective and well tolerated, many unmet needs exist in treating moderate to severe disease, and…

The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several…

Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able to…

Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are serious hospital-treated infections associated with high rates of multi-drug resistant (MDR) bacteria, including…

The increasing prevalence and severity of Gram-negative infections (GNIs) caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens have emerged as a global public health concern…

For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient…

Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease…

Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease…

The therapeutic landscape for recurrent or metastatic SCCHN has benefited from the introduction of only one novel treatment in the past several years, Erbitux in 2011. Although Erbitux has improved…

Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival…